Spots Global Cancer Trial Database for A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Official Title: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics Of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Study ID: NCT01290549
Study Description
Brief Summary: This is a Phase I, multicenter, open-label, dose-escalation study of polatuzumab vedotin administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory hematologic malignancies. In Phase Ib, participants will receive polatuzumab vedotin in combination with rituximab.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford Cancer Center, Stanford, California, United States
Stanford Cancer Institute Pharmacy, Stanford, California, United States
Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States
Roswell Park Cancer Inst., Buffalo, New York, United States
Sarah Cannon Cancer Center, Germantown, Tennessee, United States
M.D Anderson Cancer Center; Oncology, Houston, Texas, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada
British Columbia Cancer Agency, Vancouver, British Columbia, Canada
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada
CHU Dijon - SCE Hemato, Dijon, , France
Centre Hospitalier Regional Universitaire de Lille, Lille, , France
CHU Lapeyronie, Hematologie, Montpellier, , France
Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, , France
Centre Henri Becquerel; Hematologie, Rouen, , France
Academisch Medisch Centrum; Hematologie, Amsterdam, , Netherlands
Contact Details
Name: Yu-Waye Chu, M.D.
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
